Paris-based kyron.bio has announced a €5.5M funding round, led by HCVC, aimed at addressing challenges in biologic drug development by controlling glycan molecules on drug surfaces. The funding will facilitate platform development, team expansion, and preclinical studies, coinciding with the launch of the company's EIC Transition project. Kyron.bio is focused on antibody therapeutics for diseases like cancer and autoimmune conditions, tackling the issue of immune system responses that can compromise treatment effectiveness. Their unique platform targets N-glycosylation to improve drug safety and efficacy, integrating with existing biomanufacturing methods.
Kyron.bio aims to transform biologic drug development by controlling glycans to enhance therapeutic efficacy and reduce side effects in antibody therapeutics.
The recent €5.5M funding round will enable kyron.bio to develop its technology platform, expand its team, and support preclinical studies as part of the EIC Transition project.
Collection
[
|
...
]